GlassScriptPhysician profile
Charles A Laney
NPI 1184823551
$9,627.19
in general payments reported to CMS, 2019-2025
39 companies · $2,001 in 2025
The $2,001 reported for 2025 was more than what 83% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,179 · 2020: $423 · 2021: $917 · 2022: $1,895 · 2023: $1,476 · 2024: $1,736 · 2025: $2,001.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,213.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,212.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $1,578.46 | 2019-2025 | Aveir |
| Pfizer INC. | $1,146.28 | 2019-2025 | |
| Philips North America LLC | $792.62 | 2022-2025 | (Cm9) Amb Mon & Diag Und, Ambulatory Monitoring & Diagnostics Undivided, Mcot |
| Merck Sharp & Dohme LLC | $744.53 | 2021-2025 | Verquvo, Capvaxive |
| Janssen Pharmaceuticals, INC | $610.70 | 2019-2024 | Xarelto |
| Amgen INC. | $549.52 | 2020-2025 | Repatha, Repatha |
| Novartis Pharmaceuticals Corporation | $456.84 | 2019-2024 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $449.16 | 2020-2024 | Lifevest |
| E.R. Squibb & Sons, L.L.C. | $434.53 | 2021-2025 | Camzyos, Eliquis |
| Medtronic, INC. | $416.77 | 2022-2025 | Symplicity G3, Onyx Frontier, Corevalve Evolut R |
| Sanofi-Aventis U.S. LLC | $323.14 | 2019-2024 | |
| Medtronic Vascular, INC. | $244.30 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $216.65 | 2019-2025 | Jardiance |
| Irhythm Technologies, INC. | $200.15 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $176.43 | 2019-2023 | Farxiga |
Show all 39 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $152.67 | 2023-2025 | Wegovy, Rybelsus, Ozempic |
| Boston Scientific Corporation | $139.30 | 2023-2025 | Watchman Flx, Resonate El Icd Vr |
| Abiomed | $116.20 | 2025 | |
| Endologix LLC | $111.26 | 2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $96.78 | 2022-2025 | |
| Astellas Pharma US INC | $87.94 | 2019-2022 | |
| Regeneron Healthcare Solutions, INC. | $66.18 | 2019 | |
| Inspire Medical Systems, INC. | $61.65 | 2025 | Inspire |
| Kowa Pharmaceuticals America, INC. | $60.28 | 2019-2022 | |
| Lexicon Pharmaceuticals, INC. | $57.13 | 2023-2024 | Inpefa |
| Angiodynamics, INC. | $43.52 | 2022 | |
| Edwards Lifesciences Corporation | $38.17 | 2024 | Edwards Sapien 3 Ultra Transcatheter Heart Valve |
| Impulse Dynamics (USA) INC. | $36.69 | 2022-2023 | Optimizer |
| Cvrx, INC. | $33.92 | 2022-2025 | Barostim Neo System |
| Gilead Sciences, INC. | $30.48 | 2019 | |
| Silk Road Medical, INC. | $20.37 | 2021 | |
| Terumo Medical Corporation | $19.79 | 2024 | Glidewire |
| Alnylam Pharmaceuticals INC. | $19.13 | 2025 | Amvuttra |
| Atricure, INC. | $18.81 | 2023 | |
| Baxter Healthcare | $16.65 | 2025 | Hillrom - Cardiac Ambulatory Monitor |
| Merit Medical Systems INC | $16.28 | 2023 | Laureate Hydrophilic Guide Wires |
| Arbor Pharmaceuticals, INC. | $15.94 | 2021 | |
| Preventice Services, LLC | $14.21 | 2021 | |
| Esperion Therapeutics, INC. | $13.76 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Charles Laney listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.